Palisade Bio Promotes J.D. Finley to Chief Executive Officer
Carlsbad, CA, June 01, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that J.D. Finley has been named Chief Executive Officer (CEO), effective today. Mr. Finley has been serving as interim CEO since October 2022.
“Since assuming the role of interim CEO, J.D. has demonstrated leadership and operational excellence as we have navigated through a difficult transitional period. Palisade has never been stronger, and under his leadership the Company has made significant progress in the clinical advancement of LB1148. We are pleased to officially name J.D. as CEO and we look forward to his continued contributions to the company,” commented James R. Neal, Chairman of the Palisade Bio Board of Directors.
“Over the course of the last several months, we have worked diligently to identify a path to regulatory approval and commercialization. We continue to believe there is great potential for LB1148 to transform the way physicians mitigate the risks of acute and chronic GI complications from surgery. I am grateful for the continued support of all our stakeholders, and look forward to an exciting year ahead,” added Mr. Finley.
About Palisade Bio
The Company’s lead program, LB1148, is a broad-spectrum serine protease inhibitor that acts to neutralize digestive enzymes, potentially reduing intestinal damage. In prior clinical studies, LB1148 has demonstrated positive results in reducing the incidence and severity of post-surgical abdominal adhesions and potentially reducing the time to return of postoperative bowel function. LB1148’s current U.S. Phase 2 study is evaluating its effectiveness in reducing intra-abdominal adhesions, accelerating return of gastrointestinal function, and the prevention of post-operative ileus in subjects undergoing elective bowel resection (PROFILE).
The Company believes that addressing the disruption of the intestinal barrier can fundamentally change the way diseases are treated and establish new standards of patient care. For more information, please go to www.palisadebio.com.
Forward Looking Statements
Investor Relations Contact
JTC Team, LLC
Source: Palisade Bio
Keynote Presentation: How One City Got Smarter Using IoT
Government & Enterprise Using LoRaWAN for Logistics, Manufacturing, and Smart Refrigeration. How LoRAWAN Enables Regulation and Compliance
Todayâ€™s Reality: Protecting Businesses from Hackers, Ransomware, and Insider Threats